Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. (APLS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
apls · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Apellis Pharmaceuticals, Inc. (APLS) measures how much investors pay for each dollar of the company's trailing earnings. APLS's current PE ratio of 38.80x is calculated by dividing its stock price of $41.03 by its TTM earnings per share of $1.06. −72.6% discount vs 5Y avg 141.4x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2013 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Apellis Pharmaceuticals, Inc.You APLS | $5.3B | 38.80x | — | $1.06 |
 Adaptive Biotechnologies Corporation ADPT | $2.7B | N/A | — | -$0.39 |
 Agios Pharmaceuticals, Inc. AGIO | $1.7B | N/A | — | -$7.12 |
 Beam Therapeutics Inc. BEAM | $3.0B | N/A | — | -$0.81 |
 Cidara Therapeutics, Inc. CDTX | $5.6B | N/A | — | -$26.75 |
 Catalyst Pharmaceuticals, Inc. CPRX | $3.8B | 13.32x | — | $1.75 |
 IDEAYA Biosciences, Inc. IDYA | $2.5B | N/A | — | -$1.28 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 141.40x | $0.18 | — | |
2024-12-31 FY2024 | — | $-1.60 | — | |
2023-12-31 FY2023 | — | $-4.45 | — | |
2022-12-31 FY2022 | — | $-6.15 | — | |
2021-12-31 FY2021 | — | $-8.84 | — | |
2020-12-31 FY2020 | — | $-4.59 | — | |
2019-12-31 FY2019 | — | $-4.90 | — | |
2018-12-31 FY2018 | — | $-2.34 | — | |
2017-12-31 FY2017 | — | $-1.49 | — | |
2016-12-31 FY2016 | — | $-1.50 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Apellis Pharmaceuticals, Inc. (APLS) measures how much investors pay for each dollar of the company's trailing earnings. APLS's current PE ratio of 38.80x is calculated by dividing its stock price of $41.03 by its TTM earnings per share of $1.06.
Frequently asked questions
APLS pe ratio · 6 questionsAPLS's current PE ratio is 38.80x as of 2026-06-08, based on a stock price of $41.03 and TTM EPS of $1.06. Data sourced from Financial Modeling Prep via APLS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Apellis Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08